31,526 Shares in Danaher Corporation $DHR Purchased by Murphy Middleton Hinkle & Parker Inc.

Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,526 shares of the conglomerate’s stock, valued at approximately $6,985,000. Danaher makes up approximately 2.8% of Murphy Middleton Hinkle & Parker Inc.’s investment portfolio, making the stock its 7th largest holding.

A number of other institutional investors have also made changes to their positions in DHR. EP Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter worth about $3,807,000. Puzo Michael J acquired a new position in shares of Danaher in the second quarter worth about $8,624,000. Madison Asset Management LLC purchased a new position in Danaher in the second quarter valued at about $85,451,000. First Nebraska Trust Co purchased a new position in Danaher in the second quarter valued at about $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new stake in Danaher during the 3rd quarter valued at approximately $592,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Evercore reiterated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Stifel Nicolaus decreased their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Morgan Stanley raised their price target on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Price Performance

DHR opened at $231.52 on Friday. The company has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The company has a 50-day moving average of $213.55 and a 200-day moving average of $195.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.77 earnings per share. Equities analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.